Pfizer Inc. today announced detailed results from the pivotal Phase 3 TALAPRO-3 study of TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI® ...
Hong Kong Science Park-based Immuno Cure Group has inaugurated a dedicated research facility for its HIV therapeutic DNA ...
Arabian Post on MSN
Immuno Cure Deploys Scientist Team to
Another significant step towards the success of ICVAX®HONG KONG SAR – Media OutReach Newswire – 27 May 2026 – Immuno Cure Group (“Immuno Cure“), headquartered at Hong Kong Science Park, is pleased to ...
EX103: A newly designed CD20×CD3 molecule in heavily pre-treated patients with B-cell non-Hodgkin lymphoma from a phase I/II trial. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I ...
The growth of the pulmonary arterial hypertension market is mainly driven by rising disease awareness, advances in targeted ...
Use of artificial intelligence–assistance software for HER2-low and HER2-ultralow IHC interpretation training to improve diagnostic accuracy of pathologists and expand patients' eligibility for ...
Blood Cancer United announced today that new data across its portfolio of funded research will be presented in more than 50 abstracts at the 2026 American Society of Clinical Oncology (ASCO) Annual ...
Copyright: © 2026 The Author(s). Published by Elsevier Ltd.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results